CU Medicine studies show oral antiviral drug Paxlovid reduces post-COVID death risk by 42% in immunocompromised patients and its synergy with vaccination
Two recent studies conducted by researchers at The Chinese University of Hong Kong (CUHK)’s Faculty of Medicine (CU Medicine) have…